logo
Plus   Neg
Share
Email

Belden Raises FY18 Adj. EPS Outlook - Quick Facts

Belden Inc. (BDC) said Wednesday it is on track to meet its commitments for the full year 2018, and are well-positioned for longer term success.

The company expects fiscal 2018 adjusted earnings in a range of $6.28 to $6.48 per share, compared to the prior guidance range of $6.23 to $6.48 per share. Adjusted revenues for the full year are now expected between $2.643 billion and $2.673 billion, compared to prior guidance range of $2.633 billion to $2.683 billion.

On average, 11 analysts polled by Thomson Reuters expect the company to report earnings of $6.36 per share on revenues of $2.65 billion for the year. Analysts' estimates typically exclude special items.

The company also projects third-quarter adjusted earnings in a range of $1.65 to $1.75 per share and adjusted revenues between $670 million and $690 million. Street is looking for earnings of $1.70 per share on revenues of $679.71 million for the quarter.

Further, the company expects improved organic growth, solid margin expansion, and double-digit earnings per share growth in the second half of the year.

For the second quarter, net income attributable to Belden common stockholders decreased to $20.14 million or $0.49 per share from $27.24 million or $0.64 per share in the prior-year quarter. Adjusted earnings were $1.52 per share, compared to last year's $1.29 per share.

Revenues for the quarter increased 9.5 percent to $668.6 million from last year's $610.6 million. Adjusted revenues totaled $671.4 million.

Analysts expected quarterly earnings of $1.46 per share on sales of $662.1 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration has granted accelerated approval to Tazverik for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Epithelioid sarcoma is a rare sub-type of soft... STIHL recalls about 16,400 STIHL RE 90 pressure washers due to injury hazard. According to the company, the recalled pressure washer nozzle can disconnect from the spray wand when under pressure during use, posing an injury hazard. STIHL said it received seven reports of the nozzle detaching from... CVS Health Corp. launched 13 new HealthHUB locations in CVS Pharmacy stores across Philadelphia and South New Jersey. The healthcare company said it developed the HealthHUB store format to help people manage chronic conditions more conveniently and affordably. The store also features health and wellness products, clinical services and expertise.
RELATED NEWS
Follow RTT
>